RSS-Feed abonnieren

DOI: 10.1055/s-0045-1812851
HER2 Low Status and Intratumoral Heterogeneity in Epithelial Malignancies and Their Therapeutic Implications
Authors

Abstract
Human epidermal growth factor receptor 2 (HER2) continues to serve as a critical biomarker in breast cancer, but the introduction of evolving classifications such as HER2-low and HER2-ultra-low presents both opportunities and challenges in precision oncology. Targeted therapies like trastuzumab deruxtecan have broadened treatment possibilities, yet these classifications highlight critical challenges related to standardization, diagnostic precision, and equal access to care. The heterogeneity of HER2 expression adds further complexity, often limiting therapeutic effectiveness. Additionally, the exploration of HER2 as a target in nonbreast cancers underscores the urgent need for rigorous clinical validation in diverse malignancies. To advance HER2-targeted therapies, there is a critical need for comprehensive research, improved diagnostic protocols, and strategies to ensure equitable access to innovative treatments.
Patient Consent
Patient consent is not required.
Publikationsverlauf
Artikel online veröffentlicht:
30. Oktober 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 
            References
- 1 Bai X, Sun P, Wang X. et al. Structure and dynamics of the EGFR/HER2 heterodimer. Cell Discov 2023; 9 (01) 18
- 2 Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000; 182 (02) 150-162
- 3 Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007; 26 (45) 6469-6487
- 4 Andrulis IL, Bull SB, Blackstein ME. et al; Toronto Breast Cancer Study Group. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998; 16 (04) 1340-1349
- 5 Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 2023; 22 (02) 101-126
- 6 Wolff AC, Somerfield MR, Dowsett M. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol 2023; 41 (22) 3867-3872
- 7 Roy AM, Kumarasamy VM, Dhakal A, O'Regan R, Gandhi S. A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm. Cancer 2023; 129 (18) 2773-2788
- 8 Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res 2024; 12 (01) 16
- 9 Curigliano G, Dent R, Earle H. et al. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer. ESMO Open 2024; 9 (04) 102989
- 10 Polónia A, Caramelo A. HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity. Mod Pathol 2021; 34 (08) 1478-1486
- 11 Perez EA, Barrios C, Eiermann W. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol 2017; 35 (02) 141-148
- 12 Hou Y, Nitta H, Li Z. HER2 gene protein assay is useful to determine HER2 status and evaluate HER2 heterogeneity in HER2 equivocal breast cancer. Am J Clin Pathol 2017; 147 (01) 89-95
- 13 Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 2021; 72: 123-135
- 14 Sanguedolce F, Zanelli M, Palicelli A. et al. HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role. Int J Mol Sci 2023; 24 (04) 3720
- 15 Chang Y, Zhao D, Wang Z. et al. Expression of HER2 in urothelial carcinoma and its significance. Curr Urol 2025; 19 (03) 201-207
- 16 Ma C, Wang X, Guo J, Yang B, Li Y. Challenges and future of HER2-positive gastric cancer therapy. Front Oncol 2023; 13: 1080990
- 17 Pous A, Notario L, Hierro C, Layos L, Bugés C. HER2-positive gastric cancer: the role of immunotherapy and novel therapeutic strategies. Int J Mol Sci 2023; 24 (14) 11403
- 18 Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015; 34 (01) 157-164
- 19 Meric-Bernstam F, Makker V, Oaknin A. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024; 42 (01) 47-58
- 20 Bang Y-J, Van Cutsem E, Feyereislova A. et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742) 687-697
- 21 McAlpine JN, Wiegand KC, Vang R. et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009; 9: 433
- 22 Andrikopoulou A, Zagouri F, Goula K. et al. Real-world evidence of trastuzumab deruxtecan (T-DXd) efficacy in HER2-expressing gynecological malignancies. BMC Cancer 2024; 24 (01) 1503
- 23 Kim YN, Chung YS, Park E, Lee ST, Lee JY. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer. Sci Rep 2024; 14 (01) 7992
- 24 Bonello M, Sims AH, Langdon SP. Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer. Cancer Biol Med 2018; 15 (04) 375-388
- 25 Cornelissen R, Prelaj A, Sun S. et al; ZENITH20-4 Investigators. Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, phase 2 trial (Cohort 4). J Thorac Oncol 2023; 18 (08) 1031-1041
- 26 Michaelson MD, Hu C, Pham HT. et al. A phase 1/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (Trial NRG Oncology RTOG 0524). Int J Radiat Oncol Biol Phys 2017; 97 (05) 995-1001
- 27 Choudhury NJ, Campanile A, Antic T. et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 2016; 34 (18) 2165-2171
- 28 Sheng X, Yan X, Wang L. et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 2021; 27 (01) 43-51
- 29 Javle M, Borad MJ, Azad NS. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021; 22 (09) 1290-1300
- 30 Tao Z, Li SX, Shen K, Zhao Y, Zeng H, Ma X. Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 prospective clinical trials. Clin Drug Investig 2019; 39 (01) 27-43
- 31 Banerji U, van Herpen CML, Saura C. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019; 20 (08) 1124-1135
- 32 Sartore-Bianchi A, Lonardi S, Aglietta M. et al. Central nervous system as possible site of relapse in ERBB2-positive metastatic colorectal cancer: long-term results of treatment with trastuzumab and lapatinib. JAMA Oncol 2020; 6 (06) 927-929
- 33 Siena S, Di Bartolomeo M, Raghav K. et al; DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021; 22 (06) 779-789
- 34 Hou Y, Nitta H, Li Z. HER2 intratumoral heterogeneity in breast cancer, an evolving concept. Cancers (Basel) 2023; 15 (10) 2664
- 35 Verma S, Chapman A, Pickard LA. et al. Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a single-institution prospective cohort. Explor Target Antitumor Ther 2024; 5 (05) 1100-1109
- 36 Tuefferd M, Couturier J, Penault-Llorca F. et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007; 2 (11) e1138
- 37 Shimozaki K, Fukuoka S, Ooki A, Yamaguchi K. HER2-low gastric cancer: is the subgroup targetable?. ESMO Open 2024; 9 (09) 103679
 
     
      
         
      
    